| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
|
N Engl J Med
|
2005
|
12.99
|
|
2
|
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
|
N Engl J Med
|
2004
|
10.41
|
|
3
|
Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.
|
Lancet Oncol
|
2013
|
6.79
|
|
4
|
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
|
N Engl J Med
|
2014
|
6.76
|
|
5
|
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
|
J Natl Cancer Inst
|
2012
|
5.27
|
|
6
|
Adjuvant ovarian suppression in premenopausal breast cancer.
|
N Engl J Med
|
2014
|
5.18
|
|
7
|
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
|
N Engl J Med
|
2009
|
4.16
|
|
8
|
Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer.
|
J Clin Oncol
|
2003
|
3.90
|
|
9
|
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.
|
J Clin Oncol
|
2011
|
3.53
|
|
10
|
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
|
J Clin Oncol
|
2007
|
3.38
|
|
11
|
Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
|
J Natl Cancer Inst
|
2008
|
3.16
|
|
12
|
Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
|
J Natl Cancer Inst
|
2003
|
3.16
|
|
13
|
Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
|
J Clin Oncol
|
2006
|
3.15
|
|
14
|
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
|
J Clin Oncol
|
2008
|
3.14
|
|
15
|
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.
|
J Clin Oncol
|
2008
|
2.93
|
|
16
|
Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93.
|
J Clin Oncol
|
2005
|
2.58
|
|
17
|
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
|
Lancet Oncol
|
2011
|
2.51
|
|
18
|
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
|
Lancet Oncol
|
2007
|
2.44
|
|
19
|
Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials.
|
J Clin Oncol
|
2008
|
2.14
|
|
20
|
Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers.
|
Breast Cancer Res Treat
|
2010
|
2.14
|
|
21
|
Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index.
|
Lancet
|
2005
|
2.04
|
|
22
|
Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.
|
Breast
|
2013
|
1.94
|
|
23
|
Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
|
J Natl Cancer Inst
|
2006
|
1.89
|
|
24
|
Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors--a surrogate marker?
|
Cancer
|
2003
|
1.88
|
|
25
|
Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience.
|
J Clin Oncol
|
2005
|
1.61
|
|
26
|
Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
|
J Clin Oncol
|
2010
|
1.51
|
|
27
|
Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer.
|
Breast Cancer Res Treat
|
2010
|
1.48
|
|
28
|
Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX.
|
J Clin Oncol
|
2013
|
1.45
|
|
29
|
Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV.
|
J Clin Oncol
|
2003
|
1.38
|
|
30
|
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.
|
J Clin Oncol
|
2008
|
1.34
|
|
31
|
Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study.
|
J Clin Oncol
|
2011
|
1.31
|
|
32
|
Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93.
|
Breast Cancer Res Treat
|
2008
|
1.31
|
|
33
|
Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer.
|
J Clin Oncol
|
2011
|
1.29
|
|
34
|
Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93.
|
Ann Oncol
|
2004
|
1.28
|
|
35
|
Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century.
|
Breast Cancer Res Treat
|
2009
|
1.20
|
|
36
|
Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancer.
|
Psychooncology
|
2007
|
1.13
|
|
37
|
Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial.
|
J Clin Oncol
|
2002
|
1.10
|
|
38
|
Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
|
J Clin Oncol
|
2006
|
1.10
|
|
39
|
The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer.
|
J Clin Oncol
|
2007
|
1.10
|
|
40
|
Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial.
|
Breast
|
2010
|
1.09
|
|
41
|
A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37.
|
Clin Breast Cancer
|
2008
|
1.04
|
|
42
|
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.
|
J Clin Oncol
|
2007
|
1.04
|
|
43
|
Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.
|
J Clin Oncol
|
2012
|
1.03
|
|
44
|
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.
|
Breast Cancer Res Treat
|
2008
|
1.00
|
|
45
|
Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX.
|
Breast Cancer Res
|
2012
|
0.98
|
|
46
|
Trends in survival and excess risk of death after diagnosis of cancer in 1980-1996 in New South Wales, Australia.
|
Int J Cancer
|
2006
|
0.97
|
|
47
|
Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial.
|
Breast Cancer Res Treat
|
2010
|
0.97
|
|
48
|
Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
|
Cancer
|
2003
|
0.91
|
|
49
|
Prediction of cancer outcome with microarrays.
|
Lancet
|
2005
|
0.91
|
|
50
|
Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial.
|
Breast
|
2013
|
0.89
|
|
51
|
Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.
|
J Clin Oncol
|
2006
|
0.87
|
|
52
|
Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI.
|
J Clin Oncol
|
2005
|
0.87
|
|
53
|
Comparing patients' and their partners' preferences for adjuvant chemotherapy in early breast cancer.
|
Patient Educ Couns
|
2008
|
0.87
|
|
54
|
Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93.
|
Ann Oncol
|
2007
|
0.86
|
|
55
|
Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials.
|
Cancer
|
2006
|
0.85
|
|
56
|
Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone.
|
Springerplus
|
2013
|
0.85
|
|
57
|
Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group.
|
Eur J Cancer
|
2008
|
0.84
|
|
58
|
Lack of prognostic significance of "classic" lobular breast carcinoma: a matched, single institution series.
|
Breast Cancer Res Treat
|
2008
|
0.83
|
|
59
|
Molecular biomarkers to individualise treatment: assessing the evidence.
|
Med J Aust
|
2009
|
0.83
|
|
60
|
Cancer prevention: a global perspective.
|
J Clin Oncol
|
2005
|
0.82
|
|
61
|
Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy.
|
Breast Cancer Res Treat
|
2009
|
0.81
|
|
62
|
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
|
Breast Cancer Res Treat
|
2015
|
0.79
|
|
63
|
What are the long-term effects of chemotherapy and hormonal therapy for early breast cancer?
|
Nat Clin Pract Oncol
|
2005
|
0.78
|
|
64
|
Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group.
|
Support Care Cancer
|
2007
|
0.78
|
|
65
|
The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.
|
Breast Cancer Res Treat
|
2011
|
0.76
|
|
66
|
Screening decreases prostate cancer death: first analysis of the 1988 Quebec Prospective Randomized Controlled Trial.
|
Med J Aust
|
2004
|
0.76
|
|
67
|
Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences.
|
Breast Cancer Res Treat
|
2014
|
0.75
|
|
68
|
Developing a core clinical data set for cancer.
|
Med J Aust
|
2003
|
0.75
|